Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis

F Campanile, D Bongiorno, M Falcone, F Vailati, M B Pasticci, M Perez, A Raglio, F Rumpianesi, C Scuderi, F Suter, M Venditti, C Venturelli, V Ravasio, M Codeluppi, S Stefani, F Campanile, D Bongiorno, M Falcone, F Vailati, M B Pasticci, M Perez, A Raglio, F Rumpianesi, C Scuderi, F Suter, M Venditti, C Venturelli, V Ravasio, M Codeluppi, S Stefani

Abstract

Bloodstream infections due to Staphylococcus aureus (BSI) are serious infections both in hospitals and in the community, possibly leading to infective endocarditis (IE). The use of glycopeptides has been recently challenged by various forms of low-level resistance. This study evaluated the distribution of MSSA and MRSA isolates from BSI and IE in 4 Italian hospitals, their antibiotic susceptibility--focusing on the emergence of hVISA--and genotypic relationships. Our results demonstrate that the epidemiology of MRSA is changing versus different STs possessing features between community-acquired (CA)- and hospital-acquired (HA)-MRSA groups; furthermore, different MSSA isolated from BSI and IE were found, with the same backgrounds of the Italian CA-MRSA. The hVISA phenotype was very frequent (19.5%) and occurred more frequently in isolates from IE and in both the MSSA and MRSA strains. As expected, hVISA were detected in MRSA with vancomycin minimum inhibitory concentrations (MICs) of 1-2 mg/l, frequently associated with the major SCCmec I and II nosocomial clones; this phenotype was also detected in some MSSA strains. The few cases of MR-hVISA infections evaluated in our study demonstrated that 5 out of 9 patients (55%) receiving a glycopeptide, died. Future studies are required to validate these findings in terms of clinical impact.

References

    1. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, Casalta JP, Danchin N, Delahaye F, Etienne J, Le Moing V, Leport C, Mainardi JL, Ruimy R, Vandenesch F. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002;288(1):75–81. doi: 10.1001/jama.288.1.75.
    1. Chi C, Wang SM, Lin CC, Liu CC. Microbiological characteristics of community-associated Staphylococcus aureus causing uncomplicated bacteremia and infective endocarditis. J Clin Microbiol. 2010;48(1):292–294. doi: 10.1128/JCM.01788-09.
    1. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006;57(4):699–704. doi: 10.1093/jac/dkl030.
    1. Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother. 2009;64(5):1024–1028. doi: 10.1093/jac/dkp319.
    1. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis. 2010;10:159–165. doi: 10.1186/1471-2334-10-159.
    1. Bae IG, Federspiel JJ, Miró JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S, Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL, Corey GR, Fowler VG. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis. 2009;200(9):1355–1366. doi: 10.1086/606027.
    1. Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Moreillon P. Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(1):385–387. doi: 10.1128/AAC.00811-10.
    1. Moise PA, Smyth DS, Robinson DA, El-Fawal N, McCalla C, Sakoulas G. Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies. J Antimicrob Chemother. 2009;63(5):873–876. doi: 10.1093/jac/dkp047.
    1. Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293(24):3012–3021. doi: 10.1001/jama.293.24.3012.
    1. Yoon HJ, Choi JY, Kim CO, Kim JM, Song YG. A comparison of clinical features and mortality among methicillin-resistant and methicillin-sensitive strains of Staphylococcus aureus endocarditis. Yonsei Med J. 2005;46(4):496–502. doi: 10.3349/ymj.2005.46.4.496.
    1. Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, O’Donnell A, Wagener MM, Yu VL. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine. 2003;82(5):322–332. doi: 10.1097/01.md.0000091185.93122.40.
    1. Hill EE, Peetermans WE, Vanderschueren S, Claus P, Herregods MC, Herijgers P. Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis. Eur J Clin Microbiol Infect Dis. 2008;27(6):445–450. doi: 10.1007/s10096-007-0458-2.
    1. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–638. doi: 10.1086/313753.
    1. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi: 10.1016/j.ajic.2008.03.002.
    1. Clinical and Laboratory Standard Institutes (2011) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement M100-S21. CLSI, Wayne, PA, USA
    1. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical Breakpoints (2011) (Accessed 5 May 2011)
    1. Campanile F, Bongiorno D, Borbone S, Stefani S. Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob. 2009;8:22–31. doi: 10.1186/1476-0711-8-22.
    1. Campanile F, Borbone S, Perez M, Bongiorno D, Cafiso V, Bertuccio T, Purrello S, Nicolosi D, Scuderi C, Stefani S. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents. 2010;36(5):415–419. doi: 10.1016/j.ijantimicag.2010.06.044.
    1. Campanile F, Bongiorno D, Borbone S, Stefani S. Methicillin-resistant Staphylococcus aureus (MRSA) evolution: the multiple facets of an old pathogen. Eur Infect Dis. 2010;4(1):70–76.
    1. Vidal PM, Trindade PA, Garcia TO, Pacheco RL, Costa SF, Reinert C, Hiramatsu K, Mamizuka EM, Garcia CP, Levin AS. Differences between “classical” risk factors for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and risk factors for nosocomial bloodstream infections caused by multiple clones of the staphylococcal cassette chromosome mec type IV MRSA strain. Infect Control Hosp Epidemiol. 2009;30(2):139–145. doi: 10.1086/593954.
    1. Valsesia G, Rossi M, Bertschy S, Pfyffe GE. Emergence of SCCmec type IV and SCCmec type V methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leukocidin genes in a large academic teaching hospital in central Switzerland: external invaders or persisting circulators? J Clin Microbiol. 2010;48(3):720–727. doi: 10.1128/JCM.01890-09.
    1. Bassetti M, Nicco E, Malgorzata M, Viscoli C, Valbusa A, Bongiorno D, Campanile F, Stefani S. Community associated methicillin resistant Staphylococcus aureus (CA-MRSA) infective endocarditis in Italy. J Infect. 2010;61(4):353–355. doi: 10.1016/j.jinf.2010.07.014.
    1. Okon KO, Basset P, Uba A, Lin J, Oyawoye B, Shittu AO, Blanc DS. Cooccurrence of predominant Panton-Valentine leukocidin-positive sequence type (ST) 152 and multidrug-resistant ST 241 Staphylococcus aureus clones in Nigerian hospitals. J Clin Microbiol. 2009;47(9):3000–3003. doi: 10.1128/JCM.01119-09.
    1. Pérez-Roth E, Alcoba-Flórez J, López-Aguilar C, Gutiérrez-González I, Rivero-Pérez B, Méndez-Alvarez S. Familial furunculosis associated with community-acquired leukocidin-positive methicillin-susceptible Staphylococcus aureus ST152. J Clin Microbiol. 2010;48(1):329–332. doi: 10.1128/JCM.00622-09.
    1. Borbone S, Campanile F, Bongiorno D, Stefani S. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2010;65(3):591–594. doi: 10.1093/jac/dkp483.
    1. Sanchini A, Campanile F, Monaco M, Cafiso V, Rasigade JP, Laurent F, Etienne J, Stefani S, Pantosti A. DNA microarray-based characterization of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus from Italy. Eur J Clin Microbiol Infect Dis. 2011
    1. Wang CC, Lo WT, Chu ML, Siu LK. Epidemiological typing of community-acquired methicillin-resistant Staphylococcus aureus isolates from children in Taiwan. Clin Infect Dis. 2004;39(4):481–487. doi: 10.1086/422642.
    1. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, Bouvet A, Pocidalo JJ, Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis. 1989;159(5):938–944. doi: 10.1093/infdis/159.5.938.
    1. Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis. 2009;49(8):1169–1174. doi: 10.1086/605636.
    1. Naimi TS, Anderson D, O’Boyle C, Boxrud DJ, Johnson SK, Tenover FC, Lynfield R. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis. 2003;36(12):1609–1612. doi: 10.1086/375228.
    1. Hageman JC, Pegues DA, Jepson C, Bell RL, Guinan M, Ward KW, Cohen MD, Hindler JA, Tenover FC, McAllister SK, Kellum ME, Fridkin SK. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis. 2001;7(6):1023–1025. doi: 10.3201/eid0706.010618.
    1. Bobin-Dubreux S, Reverdy ME, Nervi C, Rougier M, Bolmström A, Vandenesch F, Etienne J. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother. 2001;45(1):349–352. doi: 10.1128/AAC.45.1.349-352.2001.
    1. Rasigade JP, Laurent F, Lina G, Meugnier H, Bes M, Vandenesch F, Etienne J, Tristan A. Global distribution and evolution of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus, 1981–2007. J Infect Dis. 2010;201(10):1589–1597. doi: 10.1086/652008.
    1. Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, O’Brien FG, Coombs GW, Pearman JW, Tenover FC, Kapi M, Tiensasitorn C, Ito T, Hiramatsu K. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002;40:4289–4294. doi: 10.1128/JCM.40.11.4289-4294.2002.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa